Search Results

Enasidenib (Idhifa®) is FDA approved for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation. The drug is approved for use with a companion diagnostic, the RealTime IDH2 Assay, which is used to detect specific mutations in the IDH2 gene in patients with AML.

Daunorubicin and cytarabine

Daunorubicin and cytarabine is a liposomal combination of daunorubicin, an anthracycline topoisomerase inhibitor, and cytarabine, a nucleoside metabolic inhibitor, that is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.

#ASH16 (Blog 1): Is the Best Yet to Come in Immunotherapy?

This is the first of a series of blogs covering the 58th ASH Annual Meeting and Exposition in San Diego (#ASH16) conference over the next few days. Check back for more news from the meeting.

Researchers Share Key Career Advice with LLS College Club Members

I recently had the privilege of moderating an LLS on Campus Researcher Panel attended by LLS college club members from nearly 30 universities across the country. These clubs bring together students interested in pursuing health-related careers and provide opportunities to hear from scientists working to better understand and treat blood cancers.

Precision Medicine and Immunotherapy @ ASCO16

The American Society of Clinical Oncology (#ASCO16) annual meeting featured several significant oral scientific presentations on the blood cancers over the weekend here in Chicago.

Split screen showing four survivors: Joan, Stephanie, Stacey, Katie

3 Things You Might Like to Know About Being Newly Diagnosed

A cancer diagnosis is a pivotal moment in a person’s lifetime.

From that point forward, it’s a part of who you are. It shapes how you think about the world—through the lens of your diagnosis and what’s important to you.

Harnessing METTL3 inhibition in acute megakaryoblastic leukemia driven by the t(1;22) fusion involving a member of the m6A writer complex

I want to understand how the t(1;22) translocation that involves a member of the m6A writer complex drives acute megakaryoblastic leukemia (AMKL). To identify culprit genes and pathways I will use multi-omics, including RNA, eCLIP, and TimeLapse Seq and proteomics. I will dissect the RBM15-MKL specific effects of a novel METTL3 inhibitor in primary murine and human AMKL in vitro and in vivo. My ultimate goal is to cure this rare infant leukemia by harnessing METTL3 inhibition.

Meet Three Women in Science Championing Myeloma Cures and Care

Nilotinib

Nilotinib is FDA approved for the treatment of

Adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.
Adult patients with chronic phase (CP) and accelerated phase (AP) Ph+ CML resistant to or intolerant to prior therapy that included imatinib.
Pediatric patients greater than or equal to 1 year of age with Ph+ CML-CP resistant or intolerant to prior tyrosine-kinase inhibitor (TKI) therapy.

Clofarabine

Clofarabine is FDA approved to treat children and young adults (1- 21 years old) with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.

Moxetumomab pasudotox-tdfk

Moxetumomab pasudotox-tdfk is FDA approved for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.

Zanubrutinib

Zanubrutinib is indicated for the treatment of adult patients with:

10 Self-Care Tips to Cope with Isolation and Stress

Whether you are self-quarantining or practicing social distancing, we all are adjusting to a new normal amid the coronavirus disease (COVID-19) pandemic. Everyone reacts differently to stressful situations. As a patient or survivor, you might be experiencing feelings of isolation, uncertainty and anxiety. As a caregiver, you might be feeling overwhelmed with navigating your loved one’s care while looking after your own needs. And as a family member, you might be feeling unsure of how you can help. This is understandable, and you are not alone.

BURLINGTON STORES RAISE RECORD-BREAKING $3.8 MILLION TO HELP FIGHT BLOOD CANCER

Burlington Stores and The Leukemia & Lymphoma Society’s (LLS) 15th consecutive year of partnership in the fight against blood cancers was a huge success, to say the least. As LLS’s #1 National Corporate Partner and Honored Friend, Burlington Stores, surpassed their $3.6 million goal by a longshot raising more than a record-breaking $3.8 million!

Another Advance for AML

The steady pace of progress in treating patients with acute myeloid leukemia (AML), still one of the most deadly blood cancers, continued with today’s U.S. Food & Drug Administration’s second approval of a drug called ivosidenib (Tibsovo) that works for patients with a specific subtype of AML.

Five Reasons to Give Thanks

The Leukemia & Lymphoma Society (LLS) exists to find cures for blood cancers and improve the quality of life of patients and their families. The fervor with which experts, patients and supporters rally around this cause is impressive and it’s only because of that synergy that we’re able to make such significant progress in saving lives.

In the spirit of Thanksgiving, we wanted to share five reasons we are giving thanks this holiday season.

The Leukemia & Lymphoma Society Earns a “Superior” Rating in New, Independent Analysis of Chronic Disease Nonprofits

The Leukemia & Lymphoma Society Honors Six Outstanding Blood Cancer Scientists with 2022 Achievement Awards

Fludarabine

Fludarabine is FDA approved to treat people who have chronic lymphocytic leukemia (CLL) who have not responded to at least one standard alkylting-agent-containing regimen or whose disease has progressed during treatment with such a regimen. This medicine may rarely cause a temporary loss of hair. After treatment with fludarabine has ended, normal hair growth should return.